Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.

Key facts

Study ID

NCT00292396

Run by

AbbVie (prior sponsor, Abbott)

People needed

180

Starts

2005-11-01

Expected to finish

2008-04-01

Last updated by the study team

2013-01-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
• Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis

You may not qualify if…

• Subject had previously received systemic or biologic anti-IL-12 therapy
• Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy
• Subject is taking or requires oral or injectable corticosteroids
• Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
• Female subject who is pregnant or breast-feeding or considering becoming pregnant

Where it is running

• Site Reference ID/Investigator# 3351 — San Diego, California, United States
• Site Reference ID/Investigator# 3347 — Alpharetta, Georgia, United States
• Site Reference ID/Investigator# 3348 — Skokie, Illinois, United States
• Site Reference ID/Investigator# 993 — Indianapolis, Indiana, United States
• Site Reference ID/Investigator# 990 — Boston, Massachusetts, United States
• Site Reference ID/Investigator# 3349 — St Louis, Missouri, United States
• Site Reference ID/Investigator# 992 — Cincinnati, Ohio, United States
• Site Reference ID/Investigator# 991 — Lake Oswego, Oregon, United States
• Site Reference ID/Investigator# 3367 — Portland, Oregon, United States
• Site Reference ID/Investigator# 3346 — Johnston, Rhode Island, United States
• Site Reference ID/Investigator# 994 — Nashville, Tennessee, United States
• Site Reference ID/Investigator# 3350 — Dallas, Texas, United States
• Site Reference ID/Investigator# 796 — Houston, Texas, United States
• Site Reference ID/Investigator# 2081 — Salt Lake City, Utah, United States
• Site Reference ID/Investigator# 3366 — Norfolk, Virginia, United States
• Site Reference ID/Investigator# 989 — Seattle, Washington, United States
• Site Reference ID/Investigator# 3361 — Halifax, Canada
• Site Reference ID/Investigator# 985 — Laval, Canada
• Site Reference ID/Investigator# 987 — London, Canada
• Site Reference ID/Investigator# 3364 — Montreal, Canada
• Site Reference ID/Investigator# 794 — North Bay, Canada
• Site Reference ID/Investigator# 988 — Québec, Canada
• Site Reference ID/Investigator# 795 — Waterloo, Canada
• Site Reference ID/Investigator# 3360 — Windsor, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.